Genetic variations have been proposed to play a role in the susceptibility to diabetic nephropathy.
Objectives:
To check for the association of genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and angiotensin converting enzyme (ACE) genes with the development of diabetic nephropathy among type 2 diabetic patients.
Methods:
Participants comprised 202 patients with type 2 diabetes, of whom 102 were affected with diabetic nephropathy. Genetic variants corresponding to MTHFR C677T, A1298C and ACE I/D genotypes were determined using the PCR technique coupled with digestion and restriction analysis.
Results:
Cases with diabetic nephropathy had a significantly higher frequency of the MTHFR 677 TT, 677 CT, ACE DD mutant genotypes compared with diabetic cases without nephropathy. Analysis of the association of studied MTHFR C677T, A1298C and ACE I/D polymorphisms with albuminuria showed that the MTHFR 677 T polymorphism, in the recessive and dominant models, was a risk factor for both micro and macroalbuminuria, while the ACE DD mutant genotype was a risk factor for microalbuminuria and the MTHFR 1298C in the dominant model only was a risk factor for macroalbuminuria.
Conclusion:
These findings indicate that ACE and MTHFR genetic polymorphisms might be considered as genetic risk factors for diabetic nephropathy among patients with type 2 diabetes.
SunJXuYZhuY. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract2004; 64: 185–190.
2.
RossingP. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep2006; 6: 479–483.
3.
ZintzarasEUhligKKoukoulisGN. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy: A meta-analysis. J Hum Genet2007; 52: 881–890.
4.
ErogluZCetinkalpSErdoganM. Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. J Diabetes Complications2008; 22: 186–190.
5.
AhluwaliaTSAhujaMRaiTS. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol2009; 28: 141–150.
6.
JayapalanJJMuniandySChanSP. Null association between ACE gene I/D polymorphism and diabetic nephropathy among multiethnic Malaysian subjects. Indian J Hum Genet2010; 16: 78–86.
7.
PetrovicDZorcMKanicV. Interaction between gene polymorphisms of renin-angiotensin system and metabolic risk factors in premature myocardial infarction. Angiology2001; 52: 247–252.
8.
RanjithNPegoraroRJRomL. Renin–angiotensin system and associated gene polymorphisms in myocardial infarction in young South African Indians. Cardiovasc J S Afr2004; 15: 22–26.
9.
DanserAHSchalekampMABaxWA. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation1995; 92: 1387–1388.
10.
MöllstenAKockumISvenssonM. The effect of polymorphisms in the renin-angiotensin-aldosterone system on diabetic nephropathy risk. J Diabetes Complications2008; 22: 377–383.
11.
TikellisCJohnstonCIForbesJM. Characterization of renal angiotensin- converting enzyme 2 in diabetic nephropathy. Hypertension2003; 41: 392–397.
12.
Ortega-PierresLEGómez GarcíaARodríguez-AyalaE. [Angiotensin 1 converting enzyme insertion/deletion gene polymorphism in a Mexican population with diabetic nephropathy]. Med Clin (Barc)2007; 129: 6–10.
13.
FödingerMHörlWHSunder-PlassmannG. Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol2000; 13: 20–33.
14.
ParvanovaAIlievIDimitrovBD. Hyperhomocysteinemia and increased risk of retinopathy: A cross-sectional, case-control study in patients with type 2 diabetes. Diabetes Care2002; 25: 2361.
15.
MtiraouiNEzzidiIChaiebM. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract2007; 75: 99–106.
ToffoliGDe MattiaE. Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics2008; 9: 1195–1206.
18.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO consultation. Geneva: World Health Organization, 2006.
19.
OvbiageleB. Microalbuminuria: Risk factor and potential therapeutic target for stroke?J Neurol Sci2008; 271: 21–28.
20.
LindpaintnerKPfefferMAKreutzR. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med1995; 332: 706–711.
21.
SiemianowiczKGminskiJGarczorzW. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. Oncol Rep2003; 10: 1341–1344.
UkincKErsozHOKarahanC. Methyltetrahydrofolate reductase C677T gene mutation and hyperhomocysteinemia as a novel risk factor for diabetic nephropathy. Endocrine2009; 36: 255–261.
24.
HuSGanPLiJ. [The relationship between the mutation of methylenetetrahydrofolate reductase gene 677C–>T and the diabetic microangiopathy]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi2001; 18: 118–121.
25.
SunJXuYZhuY. [The association of methylenetetrahydrofolate reductase gene polymorphism with nephropathy in type 2 diabetes mellitus in Chinese]. Zhonghua Nei Ke Za Zhi2001; 40: 529–532.
26.
WangLWangJXueY. [Relationship between methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi2001; 18: 276–278.
27.
KsiazekPBednarek-SkublewskaABuraczyńskaM. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit2004; 10: BR47–BR51.
28.
RahimiMHasanvandARahimiZ. Synergistic effects of the MTHFR C677T and A1298C polymorphisms on the increased risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem2010; 43: 1333–1339.
29.
NeugebauerSBabaTWatanabeT. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet1998; 352: 454.
30.
FujisawaTIkegamiHKawaguchiY. Meta analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia1998; 41: 47–53.
31.
NgDPTaiBCKohD. Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: A meta analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia2005; 48: 1008–1016.
32.
MovvaSAlluriRVKomandurS. Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with type 2 diabetes mellitus in Asian Indians. J Diabetes Complications2007; 21: 237–241.
33.
ViswanathanV. Prevention of diabetic nephropathy: A diabetologist’s perspective. Indian J Nephrol2004; 14: 157–162.
34.
NareshVVReddyALSivaramakrishnaG. Angiotensin converting enzyme gene polymorphism in type II diabetics with nephropathy. Indian J Nephrol2009; 19: 145–148.
35.
TarnowLGluudCParvingHH. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant1998; 13: 1125–1130.
36.
KunzRBorkJPFritscheL. Association between the angiotensin-converting enzyme insertion/deletion polymorphism and diabetic nephropathy: A methodologic appraisal and systematic review. J Am Soc Nephrol1998; 9: 1653–1663.
37.
HadjadjSBelloumRBouhanickB. Prognostic value of angiotensin I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: A prospective study. J Am Soc Nephrol2001; 12: 541–549.
38.
UddinMAzamMChowdhuryN. AngiotensinI-converting enzyme gene polymorphism in type 2 diabetic patients with nephropathy. J Med Sci2007; 7: 682–685.
39.
JacobsenPRossingKRossingP. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int1998; 53: 1002–1006.
40.
ParvingHHJacobsenPTarnowL. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study. BMJ1996; 313: 591–594.
41.
PernaARuggenentiPTestaA. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int2000; 57: 274–281.
42.
FujitaHNaritaTMeguroH. No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type II diabetic patients with proliferative diabetic retinopathy. J Diabetes Complications1999; 13: 284–287.
43.
OdawaraMYamashitaKYamadaN. MTHFR gene variant is not associated with diabetic nephropathy in Japanese. Nucleic Acids Symp Ser1999; 42: 85–86.
44.
YoshiokaKYoshidaTUmekawaTKogureA. Methylenetetrahydrofolate reductase gene polymorphism is not related to diabetic nephropathy in Japanese Type 2 diabetic patients. Diabet Med2004; 21: 1051–1052.
45.
MaedaMYamamotoIFukudaM. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications2008; 22: 119–125.
46.
ErogluZErdoganMTetikA. The relationship of the methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Metab Res Rev2007; 23: 621–624.
47.
BlüthnerMBrüntgensASchmidtS. Association of methylenetetrahydrofolate reductase gene polymorphism and diabetic nephropathy in type 2 diabetes?Nephrol Dial Transplant1999; 14: 56–57.
48.
MoczulskiDFojcikHZukowska-SzczechowskaE. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant2003; 18: 1535–1540.
49.
ShinJSOhKSKwonSK. MTHFR gene polymorphism as a risk factor for diabetic nephropathy and macrovascular disease in NIDDM patient. Korean J Med2001; 61: 391–398.
50.
ShpichinetskyVRazIFriedlanderY. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr2000; 130: 2493–2497.
51.
WongTYChanJCPoonE. Lack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235Tgene polymorphism with renal function among Chinese patients with type II diabetes. Am J Kidney Dis1999; 33: 1064–1070.
52.
SchmidtSSchöneNRitzE. Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int1995; 47: 1176–1181.
53.
PfohlMFrostDKochM. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting-enzyme gene and diabetic nephropathy in IDDM patients. Horm Metab Res1998; 30: 276–280.
54.
TarnowLCambienFRossingP. Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes1995; 44: 489–494.
55.
Arzu ErgenHHatemiHAgachanB. Angiotensin-I converting enzyme gene polymorphism in Turkish type 2 diabetic patients. Exp Mol Med2004; 36: 345–350.
56.
DegirmenciIKebapciNBasaranA. Frequency of angiotensin-converting enzyme gene polymorphism in Turkish type 2 diabetic patients. Int J Clin Pract2005; 59: 1137–1142.
57.
Shin ShinYBaekSHChangKY. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract2004; 65: 257–265.
58.
RahimiZFelehgariVRahimiM. The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria. Mol Biol Rep2011; 38: 2117–2123.
59.
FelehgariVRahimiZMozafariH. ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. Mol Cell Biochem2011; 346: 23–30.
60.
Van IttersumFJde ManAMThijssenS. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol Dial Transplant2000; 15: 1000–1007.
